Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$2.47 -3.0%	$2.82	$1.84 ▼ $5.31	$85.50M	1.3	515,817 shs	262,847 shs
CBIO Crescent Biopharma	$13.93 +0.2%	$13.88	$10.83 ▼ $63.00	$272.33M	1.51	41,841 shs	35,704 shs
VNDA Vanda Pharmaceuticals	$4.46 +2.2%	$4.62	$3.81 ▼ $5.55	$262.65M	0.72	568,339 shs	185,934 shs
XOMA XOMA Royalty	$32.37 +4.8%	$26.15	$18.35 ▼ $35.00	$390.54M	1	43,205 shs	54,768 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	+4.10%	-3.79%	-7.64%	-6.96%	-41.68%
CBIO Crescent Biopharma	+7.09%	+26.36%	+8.59%	-98.19%	-98.19%
VNDA Vanda Pharmaceuticals	+1.16%	+3.32%	-12.27%	+10.94%	-14.68%
XOMA XOMA Royalty	+8.54%	+16.92%	+11.28%	+14.83%	+16.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHV Achieve Life Sciences	1.9619 of 5 stars	3.8	2.0	0.0	1.9	0.0	0.6
CBIO Crescent Biopharma	3.9996 of 5 stars	4.7	0.0	3.7	3.3	1.7	0.6
VNDA Vanda Pharmaceuticals	4.5218 of 5 stars	3.8	2.0	4.2	2.0	3.3	1.3
XOMA XOMA Royalty	4.4041 of 5 stars	3.5	4.0	3.0	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.50	Strong Buy	$14.33	481.47% Upside
CBIO Crescent Biopharma	3.40	Buy	$25.50	83.59% Upside
VNDA Vanda Pharmaceuticals	3.50	Strong Buy	$16.50	281.50% Upside
XOMA XOMA Royalty	3.00	Buy	$69.50	115.80% Upside

Current Analyst Ratings Breakdown

Latest ACHV, XOMA, CBIO, and VNDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	CBIO Crescent Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
7/14/2025	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$27.00
6/25/2025	CBIO Crescent Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/20/2025	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	CBIO Crescent Biopharma	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$22.00
5/28/2025	XOMA XOMA Royalty	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00
5/14/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$13.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$1.20 per share	N/A
CBIO Crescent Biopharma	$10K	27,154.95	N/A	N/A	$6.92 per share	2.01
VNDA Vanda Pharmaceuticals	$198.77M	1.29	N/A	N/A	$8.23 per share	0.53
XOMA XOMA Royalty	$13.05M	29.54	N/A	N/A	$6.95 per share	4.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$39.83M	-$1.46	N/A	N/A	N/A	N/A	-193.49%	-116.68%	N/A
CBIO Crescent Biopharma	-$37.88M	-$34.93	N/A	N/A	N/A	N/A	-106.06%	-86.60%	N/A
VNDA Vanda Pharmaceuticals	-$18.90M	-$1.13	N/A	N/A	N/A	-32.90%	-12.89%	-10.47%	N/A
XOMA XOMA Royalty	-$13.82M	-$1.55	N/A	N/A	N/A	-13.04%	-12.43%	-4.85%	N/A

Latest ACHV, XOMA, CBIO, and VNDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	XOMA XOMA Royalty	-$0.12	$0.48	+$0.60	$0.44	$9.39 million	$13.13 million
8/7/2025	Q2 2025	ACHV Achieve Life Sciences	-$0.37	-$0.37	N/A	-$0.37	N/A	N/A
7/31/2025	Q2 2025	CBIO Crescent Biopharma	-$2.69	-$4.93	-$2.24	-$4.93	N/A	N/A
7/31/2025	Q2 2025	VNDA Vanda Pharmaceuticals	-$0.34	-$0.46	-$0.12	-$0.46	$54.77 million	$52.59 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XOMA XOMA Royalty	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.21	6.64	6.64
CBIO Crescent Biopharma	N/A	9.21	9.21
VNDA Vanda Pharmaceuticals	N/A	3.25	3.23
XOMA XOMA Royalty	1.18	5.54	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
CBIO Crescent Biopharma	75.19%
VNDA Vanda Pharmaceuticals	88.14%
XOMA XOMA Royalty	95.92%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	3.00%
CBIO Crescent Biopharma	4.00%
VNDA Vanda Pharmaceuticals	10.00%
XOMA XOMA Royalty	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	34.69 million	33.64 million	Optionable
CBIO Crescent Biopharma	50	19.55 million	18.77 million	No Data
VNDA Vanda Pharmaceuticals	290	59.09 million	53.18 million	Optionable
XOMA XOMA Royalty	10	11.97 million	10.88 million	Optionable

ACHV, XOMA, CBIO, and VNDA Headlines

Recent News About These Companies

Xoma Corp. Reports Strong Earnings Growth in 2025

August 14 at 4:26 AM | msn.com

LAVA Therapeutics Enters Agreement to Be Acquired by XOMA Royalty Corporation and Announces Discontinuation of LAVA-1266 Development

August 13 at 5:42 PM | quiverquant.comQ

Cautious Hold Rating on Xoma Amid Strategic Acquisitions and Uncertain Growth Outlook

August 13 at 11:42 AM | tipranks.com

XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates

August 13 at 9:55 AM | zacks.com

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

August 13 at 7:30 AM | globenewswire.com

XOMA Royalty Corporation: XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11 at 2:16 PM | finanznachrichten.de

XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics

August 11 at 9:15 AM | finance.yahoo.com

XOMA Royalty (XOMA) Projected to Post Earnings on Tuesday

August 11 at 2:12 AM | americanbankingnews.com

XOMA Royalty (NASDAQ:XOMA) Upgraded to "Buy" at Wall Street Zen

August 11 at 2:21 AM | marketbeat.com

Institutional investors own a significant stake of 43% in XOMA Royalty Corporation (NASDAQ:XOMA)

August 10, 2025 | finance.yahoo.com

CM Management LLC Grows Stake in XOMA Royalty Corporation (NASDAQ:XOMA)

August 7, 2025 | marketbeat.com

XOMA Royalty (XOMA) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

I'm Staying Neutral On XOMA Royalty After The LAVA And HilleVax Deals

August 6, 2025 | seekingalpha.com

HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX

August 5, 2025 | businesswire.com

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.

August 5, 2025 | prnewswire.com

Hold Rating on XOMA’s Acquisition of LAVA Therapeutics: Valuation and Risks Assessed

August 5, 2025 | tipranks.com

XOMA Royalty (NASDAQ:XOMA) Cut to "Hold" at Wall Street Zen

August 5, 2025 | americanbankingnews.com

LAVA Therapeutics stock rises on acquisition deal with XOMA Royalty

August 4, 2025 | investing.com

Hillevax stock rises after XOMA Royalty announces acquisition

August 4, 2025 | investing.com

XOMA Royalty Corporation Enters Definitive Share Purchase Agreement to Acquire LAVA Therapeutics N.V.

August 4, 2025 | quiverquant.comQ

HilleVax to be acquired by XOMA Royalty

August 4, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHV, XOMA, CBIO, and VNDA Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$2.46 -0.08 (-2.95%)

As of 03:03 PM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Crescent Biopharma NASDAQ:CBIO

$13.93 +0.03 (+0.22%)

As of 02:19 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.46 +0.10 (+2.18%)

As of 03:03 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

XOMA Royalty NASDAQ:XOMA

$32.37 +1.48 (+4.80%)

As of 03:04 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time